Central Nervous System (CNS) Tumours
CNS Tumours Oligodendroglioma Astrocytoma Glioblastoma Glioma 1p/19q IDH1 IDH2 MGMT promoter methylation
PURPOSE OF PROGRAMME:
Testing for 1p/19q co-deletion status and/or MGMT promotor methylation and/or IDH1 / IDH2 status. Additional test information is provided for each case.
MATERIAL PROVIDED: FFPE (Formalin Fixed Paraffin Embedded sections)
DISTRIBUTIONS PER YEAR: 1
SAMPLES PER DISTRIBUTION: 4
FREQUENCY OF DISTRIBUTION: 1
PROGRAMME OF ANALYSIS:
Details of the performance criteria for this programme can be obtained from UK NEQAS Genomics (GenQA) directly.
Telephone: +44 (0) 131 2426898
GenQA (Genomics Quality Assessment) provides external quality assessment (EQA) / proficiency testing (PT) to the genomics community worldwide. GenQA EQAs cover the entire clinical genomics service from patient counselling, sample preparation, testing processes, results interpretation and reporting. Laboratories and individual clinicians have access to more than 100 unique EQAs available for a range of rare and inherited disorders and acquired diseases. Please click here for an overview of GenQA